Merck & Co. has reported a third consecutive phase 3 clinical trial win for its oral PCSK9 inhibitor enlicitide decanoate, positioning itself as a frontrunner in the race to deliver the first oral PCSK9 treatment for hyperlipidemia. The achievement marks another milestone in the company’s CORALreef program and sets the stage for regulatory submissions.
Enlicitide Achieves Primary and Secondary Endpoints
The latest trial enrolled adults with high cholesterol who were already on stable lipid-lowering therapy, including statins, and who had either a history of major atherosclerotic cardiovascular disease (ASCVD) or were at high risk of a first event.
At 24 weeks, patients in the enlicitide arm experienced a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C) compared to placebo, meeting the trial’s primary endpoint. Merck also reported positive results in several secondary endpoints, including reductions in other atherogenic lipoproteins.
A New Era for Oral PCSK9 Inhibitors
If approved, enlicitide would become the first oral PCSK9 inhibitor on the market, offering an alternative to current injectable PCSK9 therapies such as Amgen’s Repatha, Sanofi-Regeneron’s Praluent, and Novartis’ Leqvio (inclisiran).
Enlicitide is a macrocyclic peptide designed to deliver antibody-like activity in oral form, overcoming long-standing challenges in targeting the PCSK9 protein. Previous attempts at oral PCSK9 inhibitors stalled due to the lack of suitable binding sites.
Competitive Landscape: Merck vs. AstraZeneca
While Merck’s three phase 3 wins put it ahead in the oral PCSK9 race, AstraZeneca is also pursuing the space with a small-molecule PCSK9 inhibitor currently in phase 3 trials. However, Merck’s progress gives it a clear lead.
On a July earnings call, Dean Li, President of Merck Research Laboratories, emphasized that enlicitide is expected not only to be first-in-class but also best-in-class, based on data seen to date from competitors.
Looking Ahead: Cardiovascular Outcomes Trial
Merck is betting heavily on enlicitide’s potential. A large cardiovascular outcomes trial involving more than 14,500 patients is underway to determine whether enlicitide can significantly reduce the risk of major cardiovascular events. The company also sees opportunities to develop combination therapies with enlicitide to further improve lipid management.
Expanded Outlook & Risks
While the string of successes for Enlicitide is compelling, challenges remain. Regulatory agencies will demand full safety and durability data. If the outcomes trial does not show a cardiovascular benefit, the commercial appeal may diminish.
Additionally, the competition is not standing still: rival oral PCSK9 candidates, small molecules, or even gene editing strategies could erode Enlicitide’s first-mover advantage.
On the opportunity side, should Enlicitide gain approval, it could dramatically alter standard of care in hyperlipidemia by making PCSK9 inhibition accessible to patients unwilling or unable to receive injections. The pill format may improve adherence and broaden the market.
As Merck prepares to submit to regulators and present full datasets, it’s trajectory will be a crucial test case in the evolution from injectables to oral biologic mimetics in cardiovascular medicine.
The broader implications of it extend beyond cholesterol management. Experts suggest that if the drug performs well in outcomes trials, it could reshape how clinicians approach cardiovascular risk reduction. Oral PCSK9 inhibition could be used earlier in the treatment cascade, potentially even before injectable therapies are considered, expanding the eligible patient population significantly.
For patients, the arrival of Enlicitide would represent a major step forward in accessibility and adherence. Unlike injections that require storage and administration logistics, an oral tablet can be integrated seamlessly into daily routines. This convenience could lead to improved treatment persistence and overall cardiovascular outcomes in the real world.
From a commercial standpoint, Enlicitide could also drive competition in pricing, potentially reducing the cost barriers that have limited broader PCSK9 adoption to date. Analysts predict that if Merck successfully secures approval and reimbursement, the oral PCSK9 market could exceed several billion dollars annually by the end of the decade.
